Japan Approves CyberKnife System For Extracranial Use - Non-Invasive Treatment Alternative For Tumors Anywhere In The Body
September 26th, 2008 by allsoch
Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted Shonin approval of the CyberKnife® Robotic Radiosurgery System for use in treatment of extracranial tumors, including tumors that move with respiration. This regulatory approval dramatically expands the types of patients that can be treated with radiosurgery. As a result of this approval, the CyberKnife System may be used in Japan to treat tumors anywhere in the body, including those in the spine, lung, liver, pancreas and prostate.
Posted in Uncategorized | No Comments »
Two studies from Canada and Brazil announced at conferences earlier this week suggest that bariatric or weight-loss surgery to control obesity may also cut cancer risk.
ORLANDO, FL (UroToday.com) - Intravesical chemotherapy and intravesical BCG both reduce the recurrence rate in patients with stage Ta, T1 bladder cancer, however the benefit of BCG relative to chemotherapy for long-term endpoints, especially in intermediate risk patients, is still controversial. The objective is to compare after transurethral resection (TUR) the long-term efficacy of 6 weekly intravesical instillations of epirubicin, bacillus Calmette-Guerin (BCG) and BCG plus isoniazid followed by 3 weekly maintenance instillations at months 3, 6, 12, 18, 24, 30 and 36 in patients with intermediate and high risk stage Ta T1 papillary bladder cancer.
The Damon Runyon Cancer Research Foundation named 14 new Damon Runyon Fellows at its May 2008 Fellowship Award Committee review. The recipients of this prestigious, three-year award are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators across the country. The Fellowship is specifically intended to encourage the nation’s most promising young investigators to pursue careers in cancer research by providing them with independent funding to work on innovative projects. The Damon Runyon Cancer Research Foundation has committed more than $200 million to support the careers of cancer researchers across the United States since the program’s inception.
BSD Medical Corp. (NASDAQ: BSDM) reported that in the Annals of Oncology (Volume 19, Supplement 2, 2008), the European Society for Medical Oncology (ESMO) Clinical Treatment Guideline Working Group has published its relevant clinical treatment guidelines under “Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up.” The guidelines highlight hyperthermia therapy as a treatment option for several types of soft tissue sarcomas. The ESMO Guidelines Working Group includes most leading clinical experts from European Comprehensive Cancer Centers such as GR Institut Gustave Roussy Villejuif (France); Istituto Nazionale Tumori Milan (Italy); Erasmus MC Daniel den Hoed Cancer Center (Rotterdam, Netherlands); UMS Heidelberg (Germany); M. Sklodowska-Curie Memorial Cancer Center Warsaw (Poland); University Hospital Gasthuisberg of the Catholic University Leuven (Belgium); Munich Grosshadern University Medical School in Munich (Germany); Royal Marsden Hospital (London, United Kingdom); Charite UMS Berlin (Germany); Norwegian Radium Hospital (Oslo, Norway); Centre Pluridisciplinaire d’Oncologie, CHUV Lausanne (Switzerland) and some sarcoma centers of excellence in the Unites States such as MD Anderson Cancer Center (Houston); Memorial Sloan-Kettering Cancer Center (New York) and Dana Faber Cancer Institute (Boston).
An international panel of medical professionals, industry specialists and scientists along with universities such as “La Sapienza,” Rome, Italy and University of Ontario, Institute of Technology, Toronto, Canada will conduct a public scientific review of Dario Crosetto’s 3D-CBS (Three Dimensional Complete Body Screening) innovative technology June 23, 2008 broadcast live via web. This breakthrough in medical imaging technology whose validity has been recognized for years by science and technology and recently confirmed by others (including Siemens, who said in 2002 that Crosetto’s claims were impossible) will permit the use of PET (Positron Emission Tomography) technology safe enough for routine examination of apparently healthy people for early detection of cancer.
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced three presentations at the Society of Nuclear Medicine (SNM) 55th Annual Meeting on preclinical data supporting its Trofex program for the detection, staging and monitoring of prostate cancer. The presentations described the synthesis, production and preclinical profile of two lead candidate compounds, MIP-1072 and MIP-1095. These compounds provide the foundation for the Company’s recently initiated clinical program and support Molecular Insight’s small molecule approach to the discovery and development of molecular imaging pharmaceuticals. Molecular Insight is conducting an exploratory clinical trial with the two lead candidates with the goal of selecting a compound for further commercial development.
Major League Baseball (MLB) and the Major League Baseball Players Association (MLBPA) are teaming up with the American Academy of Dermatology (Academy) this summer through the Play Sun SmartTM program to educate players and fans about skin cancer. The many hours spent in the midday sun playing baseball or cheering for their favorite team puts both players and fans at risk for skin cancer, a potentially life-threatening condition that affects 1 in 5 Americans.
ORLANDO, FL (UroToday.com) - Dr. Waleed Al-Khudair led this panel discussion. Should a patient with CaP be able to donate his kidney to a family member? When should a patient treated for CaP become eligible for a renal transplant? These questions were presented to the panel.
ORLANDO, FL (UroToday.com) - When should one clamp the renal hilum at partial nephrectomy?